Scotiabank Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $80.00

Sarepta Therapeutics (NASDAQ:SRPT - Free Report) had its price objective reduced by Scotiabank from $105.00 to $80.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a sector perform rating on the biotechnology company's stock.

SRPT has been the subject of several other reports. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. StockNews.com lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $167.41.

Remove Ads

Sarepta Therapeutics Stock Up 2.1 %

NASDAQ SRPT traded up $1.54 during mid-day trading on Thursday, reaching $75.64. The stock had a trading volume of 715,402 shares, compared to its average volume of 1,216,630. The company has a fifty day moving average price of $107.19 and a 200 day moving average price of $117.88. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 1 year low of $73.05 and a 1 year high of $173.25. The stock has a market cap of $7.34 billion, a PE ratio of 60.51 and a beta of 0.79.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares in the last quarter. Norges Bank purchased a new position in Sarepta Therapeutics during the 4th quarter worth $126,315,000. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth $79,425,000. Finally, Janus Henderson Group PLC grew its position in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after buying an additional 543,143 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.